FDA halts use of 2 treatments found to be ineffective against omicron
WASHINGTON — U.S. regulators restricted the use of a pair of COVID-19 monoclonal antibody therapies after scientific evidence suggested they are unlikely to be effective against the omicron variant.
The Food and Drug Administration said in a statement on Monday that it had decided to limit access to the treatments, which are made by Eli Lilly & Co. and Regeneron Pharmaceuticals Inc., amid the recent surge in omicron infections. The variant, which was first detected last year in southern Africa, now accounts for nearly all new cases of COVID-19 in the U.S.
